Literature DB >> 33655230

COVID-19 cytokine storm syndrome: a threshold concept.

Luke Y C Chen1,2, Tien T T Quach2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33655230      PMCID: PMC7906728          DOI: 10.1016/S2666-5247(20)30223-8

Source DB:  PubMed          Journal:  Lancet Microbe        ISSN: 2666-5247


× No keyword cloud information.
The COVID-19 pandemic has placed the practice of medicine at a threshold overlooking a new and different era, and has led to the evolving concept of COVID-19 cytokine storm syndrome (COVID-19-CSS). Early in the pandemic, high levels of inflammatory cytokines such as interleukin-6 (IL-6) were observed in patients with poor outcomes. Comparison with other cytokine storm syndromes, such as haemophagocytic lymphohistiocytosis (HLH), which are characterised by an excessive and deleterious immune response, led to the idea of a maladaptive immune response driving COVID-19-related morbidity and mortality. Simultaneously, support increased for testing and using immunosuppressive therapies such as cytokine blockade and JAK inhibition. However, the proposition that hypercytokinaemia is pathological has been met with scepticism—suppressing the immune response to a microbial pathogen runs counter to decades of medical teaching. Critics of COVID-19-CSS posit that hypercytokinaemia might be necessary for viral clearance and observe that median IL-6 levels are low in COVID-19 compared with other inflammatory conditions, such as acute respiratory distress syndrome (ARDS) and bacterial sepsis. Three lines of evidence have arisen to support the existence of COVID-19-CSS. First, several large studies have shown that IL-6 levels of more than 80 pg/mL are the best laboratory predictor of respiratory failure and death. Inflammatory markers such as C-reactive protein and IL-6 are important components of prognostic models, such as the ISARIC 4C model and others. In conditions for which IL-6 blockade is routinely used, such as rheumatoid arthritis and giant cell arteritis, IL-6 levels are often only modestly elevated, at less than 100 pg/mL. Second, a 2020 autopsy study of 21 patients showed that many cases of lethal COVID-19 were associated with extensive multiorgan inflammation with only sporadic presence of virus. This finding suggests a maladaptive immune response, resulting in continuous neutrophil activation and organ damage. And finally, some patients with COVID-19 benefit from immunosuppression. The first medication shown to reduce mortality was dexamethasone, although the pleiotropic effects of corticosteroids and insufficiency of detailed inflammatory marker data from the RECOVERY trial limit the degree to which it substantiates the CSS concept.3, 7 More recent studies showing benefit for tocilizumab in critically ill patients and baricitinib in hospitalised patients provide more substantial evidence that some patients with COVID-19 benefit from immunosuppressive therapies. Cytokine storm from viral infection is well accepted in rare diseases such Epstein-Barr virus-associated HLH (EBV-HLH). The standard of care in EBV-HLH is etoposide-based chemotherapy. Extending the umbrella of cytokine storm from rare diseases, such as EBV-HLH, to apply to some patients suffering from a pandemic illness is a new threshold concept. In education, threshold concepts are not merely core concepts, but rather induce a transformed understanding without which the learner cannot progress.8, 9 Threshold concepts are typically applied to established principles; however, new concepts can also transform a discipline—eg, germ theory revolutionised medicine in the late 1800s, leading to aseptic technique, abandonment of ineffective concepts such as miasmas (poisoned air), and, ultimately, effective anti-microbial therapies and vaccines. We provide a comparison of how both germ theory and COVID-19-CSS can be viewed as threshold concepts (table ).
Table

Germ theory and COVID-19-CSS as threshold concepts in medicine

Description of criterion for a threshold conceptGerm theoryCOVID-19-CSS
TransformativeThe learner or practitioner's understanding of a subject is transformed; the threshold concept is a portal of entry into a new, previously inaccessible way of thinking about the subjectSpecific microbes cause specific diseases transformed the 19th century understanding of transmissible diseaseTreating the maladaptive host immune response in addition to the microbe is a transformative concept
TroublesomeInvolves knowledge that is often alien, confronting, or counterintuitive; drastically alters one's perception of how that piece of the world worksThat microscopic organisms are responsible for human diseaseImmunosuppression in acute infection is counterintuitive, and on the surface, contradicts traditional medical teaching
IrreversibleOnce learned, a threshold concept cannot be unlearned. Subject experts might not recall their own difficulties in grasping a threshold concept and underestimate why it is problematic for novicesTheories such as miasmas (poisoned air) and abiogenesis (simple life arising from non-living material) recededOngoing work will refine the definition and treatment of COVID-19-CSS
IntegrativeBrings together different aspects of the subject that previously did not seem (to the learner or practitioner) to be related. Connections between different subjects that were previously hidden are revealedKoch's postulates integrated findings from Ehrlich, Löeffler, and others to establish a causative relationship between a microbe and a particular diseaseIntegrates established concepts (eg, EBV-HLH) with current concepts (COVID-19-CSS or COVID-19 hyperinflammation)
BoundedThe concept is limited by boundaries with other concepts and by disciplinary boundariesGerm theory was inaccurately applied to other diseases such as Hodgkin lymphomaNon-microbial CSSs (eg, GVHD, CART CRS) have limited applicability to COVID-19-CSS
DiscursiveCrossing a conceptual threshold involves enhancement and extension of discipline-specific languageNumerous neologisms arose; microbiology, bacteriology, vaccinesCOVID-19 cytokine storm syndrome; COVID-19 hyperinflammation; pathological immune activation
ReconstitutiveThe learner or practitioner's understanding is reconfigured according to the new understandingHelped usher in the modern era of scientific medicineIdentifying maladaptive immune responses will probably apply to other microbial diseases
LiminalLearners occupy a transitional liminal space characterised by oscillation between old and new conceptual understandingsGerm theory was fiercely debated for many years before it was widely acceptedThe entire discipline of medicine has been in a liminal space during the current pandemic, with ongoing controversies surrounding the definition and significance of COVID-19-CSS

CSS=cytokine storm syndrome. EBV-HLH=Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis. GVHD=graft-versus-host disease. CART CRS=chimeric antigen receptor associated cytokine release syndrome.

Germ theory and COVID-19-CSS as threshold concepts in medicine CSS=cytokine storm syndrome. EBV-HLH=Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis. GVHD=graft-versus-host disease. CART CRS=chimeric antigen receptor associated cytokine release syndrome. The concept of pathological immune activation and its therapeutic corollary, immunosuppression for the treatment of an infection, is most certainly troublesome and transformative. CSS does not apply to all patients with COVID-19. Identifying patients with immune misfiring and the most appropriate immunomodulatory therapy will require ongoing clinical trials. Given that new pandemics are certain to arise, learning how to identify and modulate maladaptive immune responses in our current liminal space is an essential learning opportunity.
  8 in total

1.  Grappling with troublesome knowledge.

Authors:  Luke Y C Chen; Gary Poole
Journal:  Med Educ       Date:  2018-06       Impact factor: 6.251

2.  From miasmas to germs: a historical approach to theories of infectious disease transmission.

Authors:  Marianna Karamanou; George Panayiotakopoulos; Gregory Tsoucalas; Antonis A Kousoulis; George Androutsos
Journal:  Infez Med       Date:  2012-03

3.  The Liminal Space.

Authors:  Rana L A Awdish
Journal:  N Engl J Med       Date:  2020-06-03       Impact factor: 91.245

4.  Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.

Authors:  Bernadette Schurink; Eva Roos; Teodora Radonic; Ellis Barbe; Catherine S C Bouman; Hans H de Boer; Godelieve J de Bree; Esther B Bulle; Eleonora M Aronica; Sandrine Florquin; Judith Fronczek; Leo M A Heunks; Menno D de Jong; Lihui Guo; Romy du Long; Rene Lutter; Pam C G Molenaar; E Andra Neefjes-Borst; Hans W M Niessen; Carel J M van Noesel; Joris J T H Roelofs; Eric J Snijder; Eline C Soer; Joanne Verheij; Alexander P J Vlaar; Wim Vos; Nicole N van der Wel; Allard C van der Wal; Paul van der Valk; Marianna Bugiani
Journal:  Lancet Microbe       Date:  2020-09-25

5.  Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.

Authors:  Brandon J Webb; Ithan D Peltan; Paul Jensen; Daanish Hoda; Bradley Hunter; Aaron Silver; Nathan Starr; Whitney Buckel; Nancy Grisel; Erika Hummel; Gregory Snow; Dave Morris; Eddie Stenehjem; Rajendu Srivastava; Samuel M Brown
Journal:  Lancet Rheumatol       Date:  2020-09-29

Review 6.  Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.

Authors:  James T England; Alym Abdulla; Catherine M Biggs; Agnes Y Y Lee; Kevin A Hay; Ryan L Hoiland; Cheryl L Wellington; Mypinder Sekhon; Shahin Jamal; Kamran Shojania; Luke Y C Chen
Journal:  Blood Rev       Date:  2020-05-15       Impact factor: 8.250

7.  Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Authors:  Daniel E Leisman; Lukas Ronner; Rachel Pinotti; Matthew D Taylor; Pratik Sinha; Carolyn S Calfee; Alexandre V Hirayama; Fiore Mastroiani; Cameron J Turtle; Michael O Harhay; Matthieu Legrand; Clifford S Deutschman
Journal:  Lancet Respir Med       Date:  2020-10-16       Impact factor: 30.700

  8 in total
  20 in total

Review 1.  Janus kinase inhibitors for the treatment of COVID-19.

Authors:  Andre Kramer; Carolin Prinz; Falk Fichtner; Anna-Lena Fischer; Volker Thieme; Felicitas Grundeis; Manuel Spagl; Christian Seeber; Vanessa Piechotta; Maria-Inti Metzendorf; Martin Golinski; Onnen Moerer; Caspar Stephani; Agata Mikolajewska; Stefan Kluge; Miriam Stegemann; Sven Laudi; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2022-06-13

Review 2.  Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges.

Authors:  Dimitrios Tsilingiris; Narjes Nasiri-Ansari; Nikolaos Spyrou; Faidon Magkos; Maria Dalamaga
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

Review 3.  The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.

Authors:  Qin Ning; Di Wu; Xiaojing Wang; Dong Xi; Tao Chen; Guang Chen; Hongwu Wang; Huiling Lu; Ming Wang; Lin Zhu; Junjian Hu; Tingting Liu; Ke Ma; Meifang Han; Xiaoping Luo
Journal:  Signal Transduct Target Ther       Date:  2022-02-23

4.  Discovering potential interactions between rare diseases and COVID-19 by combining mechanistic models of viral infection with statistical modeling.

Authors:  Macarena López-Sánchez; Carlos Loucera; María Peña-Chilet; Joaquín Dopazo
Journal:  Hum Mol Genet       Date:  2022-06-22       Impact factor: 5.121

5.  Combining immunomodulators and antivirals for COVID-19.

Authors:  Luke Y C Chen; Tien T T Quach
Journal:  Lancet Microbe       Date:  2021-06-02

Review 6.  Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis.

Authors:  Celestin Danwang; Jean Jacques Noubiap; Annie Robert; Jean Cyr Yombi
Journal:  AIDS Res Ther       Date:  2022-01-14       Impact factor: 2.250

Review 7.  The Effects of COVID-19 on the Placenta During Pregnancy.

Authors:  Habib Sadeghi Rad; Joan Röhl; Nataly Stylianou; Mark C Allenby; Sajad Razavi Bazaz; Majid E Warkiani; Fernando S F Guimaraes; Vicki L Clifton; Arutha Kulasinghe
Journal:  Front Immunol       Date:  2021-09-15       Impact factor: 8.786

Review 8.  The critical role of mesenchymal stromal/stem cell therapy in COVID-19 patients: An updated review.

Authors:  Mohsen Ebrahimi; Mohammad Taha Saadati Rad; Arghavan Zebardast; Mitra Ayyasi; Golnaz Goodarzi; Sadra Samavarchi Tehrani
Journal:  Cell Biochem Funct       Date:  2021-09-20       Impact factor: 3.685

Review 9.  The microbiota-related coinfections in COVID-19 patients: a real challenge.

Authors:  Ranjan K Mohapatra; Kuldeep Dhama; Snehasish Mishra; Ashish K Sarangi; Venkataramana Kandi; Ruchi Tiwari; Lucia Pintilie
Journal:  Beni Suef Univ J Basic Appl Sci       Date:  2021-08-21

Review 10.  Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms.

Authors:  Amy D Proal; Michael B VanElzakker
Journal:  Front Microbiol       Date:  2021-06-23       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.